With a notable shift in industry dynamics, increasing investments, and innovative breakthroughs, it appears we are witnessing signs of a significant resurgence.

A lawsuit led by a cystic fibrosis patient will see Vertex accused patent abuse and of violating patients’ human rights under the country’s constitution.

The company has received approval for Trikafta, a drug that can transform the lives of people with cystic fibrosis, but costs more than $300,000 per patient, per year.

Reflecting Singapore's growing status as a hub for Asia’s biopharmaceutical industry, Novartis has announced a $256 million expansion of its antibody manufacturing facility on the Malay peninsula.

2023 proved a tough year for biotech and pharmaceutical companies, and it seems that some companies are still having to make big decisions to stay in business.

London-based Relation Therapeutics has raised $60 million - including $35 million from the venture arm of Nvidia – to advance their technology in generating, analyzing and interpreting human data about the behaviour of genes, cells and tissues to identify new therapeutic targets and translate those into transformational medicines.

Eli Lilly and Amazon Pharmacy have announced a partnership set to enhance the delivery of Lilly’s prescription medications via a direct-to-consumer service, LillyDirect.

Recent FDA warning letters have highlighted data integrity issues at pharmaceutical manufacturing sites, particularly concerning microbiology and environmental monitoring.

Kasim Kutay, CEO of Novo Holdings, was recently interviewed by Bloomberg regarding the ongoing acquisition of Catalent, outlining Strategy 2030 and how they plan to reinvest cashflow and remain attractive to investors.

Adare Pharma Solutions, the global CDMO specializing in oral dosage forms, announced it will enhance its facility in Milan, Italy.

Tierra Biosciences has recently closed an $11 million Series A funding for its predictive AI protein engineering platform. The cash will be used to enhance capabilities in manufacturing proteins using predictive AI – across pharmaceutical, industrial and agricultural sectors.

Aspire Pharma, a UK-based company focusing on the development and enhancement of medicines, molecules and devices across a wide range of therapeutic areas, has completed the acquisition of Cenoté Pharma, a category specialist in carnitine deficiencies.

The FDA has granted breakthrough therapy status to the LSD-like substance MM120, developed by Mind Medicine Inc., to speed up the development and review for the treatment for generalized anxiety disorder (GAD).

Initially developed for type 2 diabetes - and its effectiveness in reducing food cravings and slowing stomach emptying - Wegovy has found fame in its ability to aid weight loss.

Looking forward in 2024, Fierce Pharma has published a report listing the drug patents that will expire in 2024, including for blockbusters from Bristol Myers Squibb and Biogen, plus medicines with prominent histories from Novo Nordisk, Astellas and Novartis.

Akari Therapeutics is merging with Peak Bio in an all-stock deal, creating a combined entity under the Akari Therapeutics Plc name. The merger will integrate Akari’s advanced clinical programs with Peak Bio's new drug candidates, focusing on cancer and rare diseases.

The UK's MHRA has authorized a new formulation of XGEVA (denosumab) through the new International Recognition Procedure (IRP) in just 30 days.

The MHRA recently issued new guidance designed to streamline the assessment process for established medicines, implemented since March 1, 2024.

In the last couple of weeks, there has been a flurry of news articles surrounding job layoffs at a series of pharma and biotech organizations taking drastic cost cutting measures in response to financial pressures.

KPMG Life Sciences CEO Outlook has highlighted a range of challenges predicted by CEOs in the life sciences sector. Factors such as pricing pressures and patent expirations may affect the sector's growth, with many CEOs expecting subdued growth rates.

Zeno Health has successfully raised $25 million in Series C funding, led by Korean PE firm STIC Investments and supported by existing investor Lightbox.